Pancreatic neuroendocrine tumors (NETs) inowanzo kukura zvishoma, uye rabhoritari inoongorora bundu rezviratidzo zvekukura kuburikidza nemiedzo yekufungidzira. Varwere vane NET vanopararira kunze kwepancreas vanowanzove nezviratidzo senge manyoka kana matambudziko ehomoni. Inogona kushandiswa kumishonga yakadai se octreotide, lanreotide, diazoxide, uye proton pump inhibitors, iyo inogona kudzivisa kukura kwechirwere.
When the patient’s symptoms cannot be controlled or the scan shows signs of tumarara growth, further treatment is required, and chemotherapy or targeted drugs (such as sunitinib or everolimus) can be used. For people with poorly differentiated tumors (neuroendocrine carcinoma), chemotherapy is the first choice. For patients who have spread to the liver, choose surgery or ablation technology for treatment according to their own conditions. For adults with somatostatin (a hormone) receptor-positive pancreatic neuroendocrine tumor, the radiopharmaceutical Lutathera (l Lu177 dotatate) is a treatment option.
If all feasible treatments no longer work, then consider participating in clinical trials to test new therapies. Participation in clinical trials is likely to benefit some patients.
